Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mario Sérgio Fernandes is active.

Publication


Featured researches published by Mario Sérgio Fernandes.


Leukemia & Lymphoma | 2007

Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil

Marcelo Capra; Líbia Vilella; Waldir Veiga Pereira; Virginia Maria Coser; Mario Sérgio Fernandes; Marco Antônio Schilling; Denise Almeida; Mauro Gross; Márcia Leite; Gilca Natchigal; Alice Zelmanowicz; Giorgio Adriano Paskulin; Jorge Neumann; Lucia Mariano da Rocha Silla

Rio Grande do Sul (RS), in South Brazil, with about 10 million inhabitants, is known for its agricultural activities and consequent increased human exposure to toxic agents. Patients with de novo acute myeloid leukemia (AML) were included based on information retrieved from all referral hospitals in RS between 1996 and 2000. A total of 532 patients were registered. Median age at diagnosis was 42 years. The estimated annual incidence was 1.11 cases/100 000 inhabitants/year. There was an estimated incidence of 0.5 – 1 case per 100 000 inhabitants up to the age of 45 years, and of 3.5 cases per 100 000 inhabitants aged 70 years and older, with no geographical clusters. The mean 5-year survival rate was 17% for all cases. There was an increased number of M3 cases, as already described for individuals of Latin-American and the mortality rate was similar to that described in the literature.


Revista Brasileira De Reumatologia | 2004

Imunossupressão com ciclofosfamida e fludarabina, com suporte de células tronco hematopoéticas autólogas CD-34+, para tratamento de esclerose sistêmica severa

Carlos Alberto von Mühlen; Éverton Luís Hinterholz; Bernardo Garicochea; Pedro Weingrill; Carlos H. Barrios; Mario Sérgio Fernandes; Rosângela Dahmer; Mauro Keiserman; Henrique Luiz Staub

Immune ablation of T lymphocytes, key players in the physiopathogenic processes leading to autoimmune diseases, may arrest scleroderma progression even in some severely ill patients. High-dose chemotherapy followed by autologous stem cell reinfusion - sometimes named peripheral blood stem cell transplantation - has been an effective therapy for some autoimmune diseases, including scleroderma. In this paper the authors present a patient with the diffuse form of scleroderma who received immunosuppression with cyclophosphamide 0.5 g/m² and fludarabine followed by infusion of autologous CD-34+ cells without T lymphocyte purging. This patient was followed up with cutaneous score measures, imaging and laboratory tests, as well as a well-being questionnaire. After transplantation there were major positive responses on skin and gastrointestinal tract, with cessation of diarrhea and malabsorption syndrome. These clinical improvements did not last past 6 months. We observed transitory stem cell transfusion reaction and localized herpes zoster. The patient died 12 months after the procedure due to aspirative pneumonia and gastrointestinal complications. The immunosuppressive regimen, and not the autologous stem cell transplantation, could have been responsible for the observed transitory patient improvement.


Cancer Genetics and Cytogenetics | 2004

Prevalence of TEL/AML1 fusion gene in Brazilian pediatric patients with acute lymphoblastic leukemia

P.R.G. Zen; M.C. Lima; Virginia Maria Coser; Lucia Mariano da Rocha Silla; L. Daudt; Mario Sérgio Fernandes; J. Neumann; Margarete S. Mattevi; R. Ortigara; G.A. Paskulin


Revista Brasileira De Anestesiologia | 2004

Hemophilia and anesthesia

Rafael Py Gonçalves Flores; Airton Bagatini; Ari Tadeu Lírio dos Santos; Cláudio Roberto Gomes; Mario Sérgio Fernandes; Roger Pelini Molon


Revista Brasileira De Anestesiologia | 2004

Hemofilia e anestesia

Rafael Py Gonçalves Flores; Airton Bagatini; Ari Tadeu Lírio dos Santos; Cláudio Roberto Gomes; Mario Sérgio Fernandes; Roger Pelini Molon


Blood | 2014

TKI Treatment Discontinuation: How Many Patients Could Stop Tyrosine Kinase Treatment According to Discontinuation Trials Criteria? Incidence and Prognostic Impact of Deep Molecular Response in a Cohort of Chronic Myeloid Leukemia Patients of South Brazil9s Hematology Centers

Laura Fogliatto; Marcelo Capra; Mariza Shaan; Tito Vanelli Costa; Luis Carlos Zanandrea Contin; Raquel Breunig; Juarez Fontoura Silveira; Mayde Seadi Torriani; Katia Fassina; Mario Sérgio Fernandes; Denise Almeida; Marco Antônio Schilling; Mariangela Moschen; Adriana Zardo; Moema Nene; Liane Esteves Daudt; Joao Ricardo Friedrisch; Lucia Mariano da Rocha Silla


Blood | 2014

The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Laura Fogliatto; Marcelo Capra; Mariza Shaan; Tito Vanelli Costa; Mayde Seadi Torriani; Luis Carlos Zanandrea Contin; Raquel Breunig; Katia Fassina; Mario Sérgio Fernandes; Denise Almeida; Marco Antônio Schilling; Adriana Zardo; Mariangela Moschen; Moema Nene; Juarez Fontoura Silveira; Tahiane de Brum Soares; Liane Esteves Daudt; Joao Ricardo Friedrisch; Lucia Mariano da Rocha Silla


Blood | 2013

Warning As Defiened By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?

Marcelo Capra; Mariza Shaan; Tito Vanelli Costa; Raquel Breunig; Christina G S Fraga; Mayde Seadi Torriani; Lucia Mariano da Rocha Silla; Liane Esteves Daudt; Mario Sérgio Fernandes; Denise Almeida; Marco Antônio Schilling; Katia Fassina; Sabrina Wisintainer; Mariangela Moschen; Adriana Zardo; Juliana Kratochvil; Viviane Magagnin Fernandes; Cheila Eickhoff; Moema Nene; Saozan Ahmad; Andréia Dias Almeida; Vitor Lenz


Blood | 2012

The Impact of Cytogenetic Response At 6 Months of Therapy in Global Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the South of Brazil

Laura Fogliatto; Marcelo Capra; Mariza Schaan; Mario Sérgio Fernandes; Tito Vanelli Costa; Mayde Seadi Torriani; Katia Fassina; Christina G S Fraga; Mayla Baron; Dayane Bohn Koshiyama; Natássia Machado; Liane Esteves Daudt; Lucia Mariano da Rocha Silla


Blood | 2011

The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities

Laura Fogliatto; Marcelo Capra; Mariza Shaan; Tito Vanelli Costa; Mayde Seadi Torriani; Katia Fassina; Mario Sérgio Fernandes; Denise Almeida; Marco Antônio Schilling; Virginia Maria Coser; Dalnei Veiga Pereira; Waldir Veiga Pereira; Sabrina Wisintainer; Mariangela Moschen; Adriana Zardo; Juliana Kratochvil; Viviane Magagnin Fernandes; Cheila Eickhoff; Saozan Ahmad; Andréia Dias Almeida; Moema Nene; Nathália Guterres Xavier; Dayane Bohn Koshiyama; Márcia Leite; Vitor Lenz; Liane Esteves Daudt; Lucia Mariano da Rocha Silla

Collaboration


Dive into the Mario Sérgio Fernandes's collaboration.

Top Co-Authors

Avatar

Lucia Mariano da Rocha Silla

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Denise Almeida

Universidade de Passo Fundo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adriana Zardo

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Katia Fassina

Universidade Luterana do Brasil

View shared research outputs
Top Co-Authors

Avatar

Laura Fogliatto

Universidade Federal de Ciências da Saúde de Porto Alegre

View shared research outputs
Top Co-Authors

Avatar

Liane Esteves Daudt

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Moema Nene

Universidade Federal do Rio Grande do Sul

View shared research outputs
Researchain Logo
Decentralizing Knowledge